These findings indicate that TB-500 may play a significant role in modulating inflammation, potentially offering therapeutic benefits in managing inflammatory conditions
DSIP remains a research compound in Canada and is not approved for therapeutic use, but its favorable safety profile and unique mechanism have made it increasingly popular among biohackers, athletes, and those struggling with sleep disturbances
As ALS progresses, over 80% of patients develop difficulty swallowing (dysphagia), and many also experience increased metabolism, which raises their calorie needs by about 1520% more normal (Dupuis and Chio, 2023)
This keeps antioxidant levels steady
Regulatory agencies including the FDA, TGA, and EMA have not approved BPC-157 for any indication